1. Home
  2. ELF vs BLCO Comparison

ELF vs BLCO Comparison

Compare ELF & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo e.l.f. Beauty Inc.

ELF

e.l.f. Beauty Inc.

HOLD

Current Price

$77.35

Market Cap

4.9B

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.70

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELF
BLCO
Founded
2004
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Ophthalmic Goods
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
6.0B
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
ELF
BLCO
Price
$77.35
$16.70
Analyst Decision
Buy
Hold
Analyst Count
16
14
Target Price
$130.06
$17.31
AVG Volume (30 Days)
2.3M
415.7K
Earning Date
11-05-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.40
N/A
Revenue
$1,385,640,000.00
$4,976,000,000.00
Revenue This Year
$20.59
$8.08
Revenue Next Year
$16.92
$5.77
P/E Ratio
$55.37
N/A
Revenue Growth
13.80
6.23
52 Week Low
$49.40
$10.45
52 Week High
$150.99
$20.71

Technical Indicators

Market Signals
Indicator
ELF
BLCO
Relative Strength Index (RSI) 38.97 60.30
Support Level $73.74 $16.39
Resistance Level $84.38 $17.35
Average True Range (ATR) 3.82 0.47
MACD 2.46 0.06
Stochastic Oscillator 60.55 70.25

Price Performance

Historical Comparison
ELF
BLCO

About ELF e.l.f. Beauty Inc.

e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: